[Clinical effectiveness of zotepine in treatment of negative schizophrenic symptoms. Results of an open and a double-blind controlled trial].
The clinical action of Zotepine was examined in an open and in a randomised double-blind controlled study in in-patients displaying a productive or minus pattern of symptoms within the framework of a schizophrenic disease or schizoaffective psychosis. The present paper discusses only the results achieved in treating schizophrenic minus patterns of signs and symptoms. In Study I 20 schizophrenic patients were treated with two different Zotepine dosages. Group 2 (n = 12) showed at an average daily dose of 168 +/- 15 mg (150-190 mg) a significant improvement (p less than 0.05) of the anergy subscore in the BPRS scale as well as a significant improvement of the subscores affective flattening, anhedonia/asociality and attentional imparvement in the SANS scale, compared with Group 1 (n = 8) with an average daily dose of 270 +/- 37 mg (240-340 mg). This improvement developed already during the first two weeks of the treatment. In Study II the antipsychotic action of Zotepine compared to that of perazine was studied under double-blind conditions. The average daily dose in the Zotepine group (n = 20) was around 241 +/- 70 mg (106-396 mg), in the perazin group (n = 19) at 348 +/- 09 mg (214-575 mg). With regard to the BPRS subscore anergy and all the subscores of the SANS scale, there was a distinct improvement without significant group differences. Both substances were comparably well tolerated.
Müller-Spahn
F
F
Psychiatrische Klinik der Universität Göttingen.
Dieterle
D
D
Ackenheil
M
M
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001143:Arousal / Q000187:drug effects; D001288:Attention / Q000187:drug effects; D003988:Dibenzothiepins / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010464:Perazine / Q000009:adverse effects / Q000627:therapeutic use; D010865:Pilot Projects; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D003988:Dibenzothiepins; D010464:Perazine; C022172:zotepine
Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik. Ergebnisse einer offenen und einer doppelblind-kontrollierten Studie.